scholarly journals Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology

2016 ◽  
Vol 18 (7) ◽  
pp. 859-868 ◽  
Author(s):  
Barak Zafrir ◽  
Nabeeh Salman ◽  
Maria G. Crespo-Leiro ◽  
Stefan D. Anker ◽  
Andrew J. Coats ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Surface Area ◽  
Body Surface Area ◽  
Prognostic Marker ◽  
Body Surface ◽  
European Society ◽  
Heart Failure Patients ◽  
European Society Of Cardiology

scholarly journals Effectiveness of bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: an echocardiographic study of left ventricular remodeling.

2015 ◽  
Vol 17 (2) ◽  
pp. 160 ◽  
Author(s):  
Fujian Duan ◽  
Zhi Qi ◽  
Sheng Liu ◽  
Xiuzhang Lu ◽  
Hao Wang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricle ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Ventricular Remodeling ◽  
Left Ventricular Remodeling ◽  
Left Ventricular ◽  
Lv Mass

Aims: The graft of stem cells to treat ischemic cardiomyopathy is popular in many clinical trials. The aim of this study was to evaluate the effectiveness of isolated coronary artery bypass graft combined with bone marrow mononuclear cells (BMMNC) delivered through graft vessels to improve left ventricular remodeling of patients with previous myocardial infarc- tion and chronic heart failure using echocardiography. Material and methods: Patients with previous myocardial infarction and chronic heart failure were randomly allocated to one of the two groups: CABG only (18 patients), or CABG with BMMNC transplantation (24 patients). Echocardiographic parameters were measured on B-mode imaging, 3D imaging and color flow imaging. Results Post-operative LVEDD (end-diastolic dimension of left ventricle), LVESD (end-systolic dimension of left ventricle), LVEDV (end-diastolic volume of left ventricle), LVESV (end-systolic volume of left ventricle), LVEDVI (LVEDV indexed to body surface area), LVESVI (LVESV indexed to body surface area), LV-mass (mass of left ventricle) and LV- massI (LV-mass indexed to body surface area) were significantly improved compared with those obtained prior to operation in CABG+BMMNC group (al p0.05). Postoperative mitral regurgitation score was not significantly different from those prior to opera- tion in both groups (al p>0.05). In Chi-square tests, LVEDD, LVESD, LVEDV, LVESV, LVEDVI, LVESVI, LV-mass, LV- massI were determinants of the left ventricular remodeling. Conclusion: The improvement of left ventricular remodeling in CABG+BMMNC group was better than in the CABG group and this improvement was verified by echocardiography.

scholarly journals Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

2018 ◽  
Vol 6 (6) ◽  
pp. 452-462 ◽  
Author(s):  
Marco Canepa ◽  
Candida Fonseca ◽  
Ovidiu Chioncel ◽  
Cécile Laroche ◽  
Maria G. Crespo-Leiro ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
European Society ◽  
Risk Scores ◽  
Heart Failure Patients ◽  
European Society Of Cardiology

scholarly journals Physiological monitoring in the complex multimorbid heart failure patient - Conclusions

2019 ◽  
Vol 21 (Supplement_M) ◽  
pp. M68-M71 ◽  
Author(s):  
Michael Böhm ◽  
Andrew J S Coats ◽  
Ingrid Kindermann ◽  
Ilaria Spoletini ◽  
Giuseppe Rosano
Keyword(s):  
Heart Failure ◽  
Heart Failure Patient ◽  
European Society ◽  
Healthcare Delivery ◽  
Supplement Issue ◽  
Physiological Monitoring ◽  
Heart Failure Patients ◽  
Key Points ◽  
European Society Of Cardiology ◽  
Over Time

Abstract Comorbidities are increasingly recognized as crucial components of the heart failure syndrome. Main specific challenges are polypharmacy, poor adherence to treatments, psychological aspects, and the need of monitoring after discharge. The chronic multimorbid patient therefore represents a specific heart failure phenotype that needs an appropriate and continuous management over time. This supplement issue covers the key points of a series of meeting coordinated by the Heart Failure Association of the European Society of Cardiology (ESC), that have discussed the issues surrounding the effective monitoring of our ever more complex and multimorbid heart failure patients. Here, we present an overview of the complex issues from a healthcare delivery perspective.

scholarly journals Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor

Blood ◽  
1986 ◽  
Vol 68 (5) ◽  
pp. 1114-1118 ◽  
Author(s):  
MA Goldberg ◽  
JH Antin ◽  
EC Guinan ◽  
JM Rappeport
Keyword(s):  
Heart Failure ◽  
Bone Marrow ◽  
Congestive Heart Failure ◽  
Aplastic Anemia ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Severe Combined Immunodeficiency ◽  
Group 2 ◽  
Group 1

Abstract Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide (CYA) which is usually calculated based on the patient's weight. At these high doses of CYA, serious cardiotoxicity may occur, but definitive risk factors for the development of such cardiotoxicity have not been described. Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area. Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome. Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA. Six of the 14 patients died with congestive heart failure. The dose of CYA per body surface area was calculated for all patients and the patients were divided into two groups based on daily CYA dose: Group 1, CYA less than or equal to 1.55 g/m2/d; Group 2, CYA greater than 1.55 g/m2/d. Cardiotoxicity that was thought to be related to CYA occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025). Congestive heart failure caused or contributed to death in 0/32 patients in Group 1 v 6/52 (12%) of patients in Group 2 (P less than 0.25). There was no difference in the rate of engraftment of evaluable patients in the two groups (P greater than 0.5). We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight. This study reaffirms the principle that drug toxicity correlates with dose per body surface area.

Sign in / Sign up

Export Citation Format

Share Document